Honasa buys 58% of Fluence Pharma, launches Honasa Health to enter nutraceuticals
Mamaearth parent Honasa Consumer acquires majority stake in Fluence Pharma, forming subsidiary Honasa Health to push into nutraceuticals and beauty-from-within. Fluence clocked Rs 40 cr revenue with 20%+ EBITDA margin in FY26, marking Honasa's first diversification beyond beauty and personal care.
Honasa Consumer, parent of Mamaearth, acquired 58% of Fluence Pharma to enter nutraceuticals and beauty-from-within, launching subsidiary Honasa Health. Fluence posted Rs 40 cr revenue and 20%+ EBITDA margin in FY26, diversifying Honasa beyond beauty.
Why this matters
First move outside beauty and personal care for Mamaearth's parent. Market reacted cautiously, with Honasa shares dropping 3% on the Rs 135 cr Fluence Pharma deal announcement.
Retail-company activity steady with 3,663 signals over the past 90 days.
Also reported by
- Moneycontrol — Same time
- Moneycontrol — Same time